Use of immunomagnetic reduction for C-reactive protein assay in clinical samples.
BACKGROUND
Magnetic nanoparticles biofunctionalized with antibodies are able to recognize and bind to the corresponding antigens. In this work, anti-C-reactive protein (CRP) antibody was covalently conjugated onto the surface of magnetic nanoparticles to label CRP specifically in serum.


METHODS
The level of serum CRP was detected by immunomagnetic reduction (IMR) assay, which identifies the changes in the magnetic signal representing the level of interaction between antibody-conjugated magnetic nanoparticles and CRP proteins. To investigate the feasibility of IMR for clinical application, pure CRP solutions and 40 human serum samples were tested for IMR detection of CRP to characterize sensitivity, specificity, and interference.


RESULTS
In comparison with the immunoturbidimetry assay, the results of the IMR assay indicated higher sensitivity and had a high correlation with those of the current immunoturbidimetry assay.


CONCLUSIONS
We have developed a novel and promising way to assay CRP in human serum using immunomagnetic reduction in clinical diagnosis.
Department of Laboratory Medicine, Taipei Medical University Hospital, Taipei, Taiwan.
Chien-Hsi
CH
Chang
Zhi-Xian
ZX
Lai
Hsiu-Li
HL
Lin
Che-Chuan
CC
Yang
Hsin-Hsien
HH
Chen
Shieh-Yueh
SY
Yang
Herng-Er
HE
Horng
Chin-Yih
CY
Hong
Hong-Chang
HC
Yang
Hsiu-Chen
HC
Lin
D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000032:analysis* / Q000276:immunology / Q000302:isolation & purification; D006801:Humans; D018189:Immunomagnetic Separation / Q000379:methods*; D058185:Magnetite Nanoparticles / Q000737:chemistry*; D009391:Nephelometry and Turbidimetry; D012680:Sensitivity and Specificity
D015415:Biomarkers; D058185:Magnetite Nanoparticles; D002097:C-Reactive Protein